Anti-nerve growth factor antibodies for the treatment of low back pain

References

• Chang DS, Hsu E, Hottinger DG, et al. Anti-nerve growth factor in pain management: current evidence. J Pain Res. 2016;9:373–383.
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Marks JA. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee. Osteoarthritis Cartilage. 2015 Jan;23(Suppl 1):S8–17.
   PubMed Web of Science ®Google Scholar
• Hartvigsen J, Hancock MJ, Kongsted A, et al. What low back pain is and why we need to pay attention. Lancet. 2018 June 9;391(10137):2356–2367.
   PubMed Web of Science ®Google Scholar
• Maher C, Underwood M, Buchbinder R. Non-specific low back pain. Lancet. 2017 Feb 18;389(10070):736–747.
   PubMed Web of Science ®Google Scholar
• Chou R, Deyo R, Friedly J, et al. Systemic pharmacologic therapies for low back pain: a systematic review for an American college of physicians clinical practice guideline. Ann Intern Med. 2017 Apr 4;166(7):480–492.
   PubMed Web of Science ®Google Scholar
• Chaparro LE, Furlan AD, Deshpande A, et al. Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst Rev. 2013 Aug;27(8):Cd004959.
   Google Scholar
• Abdel Shaheed C, Maher CG, Williams KA, et al. Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain: a systematic review and meta-analysis. JAMA Intern Med. 2016 July 1;176(7):958–968.
   PubMed Web of Science ®Google Scholar
• Sharma AK, Vorobeychik Y, Wasserman R, et al. The effectiveness and risks of fluoroscopically guided lumbar interlaminar epidural steroid injections: a systematic review with comprehensive analysis of the published data. Pain Med. 2017 Feb 1;18(2):239–251.
   PubMed Web of Science ®Google Scholar
• Foster NE, Anema JR, Cherkin D, et al. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet. 2018 June 9;391(10137):2368–2383.
   PubMed Web of Science ®Google Scholar
• Denk F, Bennett DL, McMahon SB. Nerve growth factor and pain mechanisms. Ann Rev Neurosci. 2017 July;25(40):307–325.
   Web of Science ®Google Scholar
• Shinoda M, Asano M, Omagari D, et al. Nerve growth factor contribution via transient receptor potential vanilloid 1 to ectopic orofacial pain. J Neurosci. 2011 May 11;31(19):7145–7155.
   PubMed Web of Science ®Google Scholar
• Ginty DD, Segal RA. Retrograde neurotrophin signaling: Trk-ing along the axon. Curr Opin Neurobiol. 2002 June;12(3):268–274.
   PubMed Web of Science ®Google Scholar
• Mantyh PW. Bone cancer pain: from mechanism to therapy. Curr Opin Supportive and Palliative Care. 2014 June;8(2):83–90.
   PubMed Web of Science ®Google Scholar
• Baron R, Binder A, Attal N, et al. Neuropathic low back pain in clinical practice. Eur J Pain. 2016 July;20(6):861–873.
   PubMed Web of Science ®Google Scholar
• Farrar JT, Young JP Jr., LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001 Nov;94(2):149–158.
   PubMed Web of Science ®Google Scholar
• Freemont AJ, Watkins A, Le Maitre C, et al. Nerve growth factor expression and innervation of the painful intervertebral disc. J Pathol. 2002 July;197(3):286–292.
   PubMed Web of Science ®Google Scholar
• Schmelz M, Mantyh P, Malfait AM, et al. Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety. Pain. 2019 Oct;160(10):2210–2220.
   PubMed Web of Science ®Google Scholar
• Burma NE, Leduc-Pessah H, Fan CY, et al. Animal models of chronic pain: advances and challenges for clinical translation. J Neurosci Res. 2017 June;95(6):1242–1256.
   PubMed Web of Science ®Google Scholar
• Nagakura Y. The need for fundamental reforms in the pain research field to develop innovative drugs. Expert Opin Drug Discov. 2017 Jan;12(1):39–46.
   PubMed Web of Science ®Google Scholar
• Hooten WM, Cohen SP. Evaluation and treatment of low back pain: a clinically focused review for primary care specialists. Mayo Clin Proc. 2015 Dec;90(12):1699–1718.
   PubMed Web of Science ®Google Scholar
• Obata K, Tsujino H, Yamanaka H, et al. Expression of neurotrophic factors in the dorsal root ganglion in a rat model of lumbar disc herniation. Pain. 2002 Sept;99(1–2):121–132.
   PubMed Web of Science ®Google Scholar
• Seki S, Sekiguchi M, Konno SI. Association between neurotrophic factor expression and pain-related behavior induced by nucleus pulposus applied to rat nerve root. Spine (Phila Pa 1976). 2018 Jan 1;43(1):E7–e15.
   PubMed Web of Science ®Google Scholar
• Fukuoka T, Kondo E, Dai Y, et al. Brain-derived neurotrophic factor increases in the uninjured dorsal root ganglion neurons in selective spinal nerve ligation model. J Neurosci. 2001 July 1;21(13):4891–4900.
   PubMed Web of Science ®Google Scholar
• Aoki Y, Nakajima A, Ohtori S, et al. Increase of nerve growth factor levels in the human herniated intervertebral disc: can annular rupture trigger discogenic back pain? Arth Res Therap. 2014 July 28;16(4):R159.
   PubMed Web of Science ®Google Scholar
• Kokubo Y, Uchida K, Kobayashi S, et al. Herniated and spondylotic intervertebral discs of the human cervical spine: histological and immunohistological findings in 500 en bloc surgical samples. Laboratory investigation. J Neurosurg Spine. 2008 Sept;9(3):285–295.
   PubMed Web of Science ®Google Scholar
• Lee S, Moon CS, Sul D, et al. Comparison of growth factor and cytokine expression in patients with degenerated disc disease and herniated nucleus pulposus. Clin Biochem. 2009 Oct;42(15):1504–1511.
   PubMed Web of Science ®Google Scholar
• Krock E, Rosenzweig DH, Chabot-Dore AJ, et al. Painful, degenerating intervertebral discs up-regulate neurite sprouting and CGRP through nociceptive factors. J Cell Mol Med. 2014 June;18(6):1213–1225.
   PubMed Web of Science ®Google Scholar
• Garcia-Cosamalon J, Del Valle ME, Calavia MG, et al. Intervertebral disc, sensory nerves and neurotrophins: who is who in discogenic pain? J Anat. 2010 July;217(1):1–15.
   PubMed Web of Science ®Google Scholar
• Cohen SP, Huang JH, Brummett C. Facet joint pain–advances in patient selection and treatment. Nat Rev Rheumatol. 2013 Feb;9(2):101–116.
   PubMed Web of Science ®Google Scholar
• Cohen SP. Sacroiliac joint pain: a comprehensive review of anatomy, diagnosis, and treatment. Anesth Analg. 2005 Nov;101(5):1440–1453.
   PubMed Web of Science ®Google Scholar
• Kras JV, Kartha S, Winkelstein BA. Intra-articular nerve growth factor regulates development, but not maintenance, of injury-induced facet joint pain & spinal neuronal hypersensitivity. Osteoarthritis Cartilage. 2015 Nov;23(11):1999–2008.
   PubMed Web of Science ®Google Scholar
• Barthel C, Yeremenko N, Jacobs R, et al. Nerve growth factor and receptor expression in rheumatoid arthritis and spondyloarthritis. Arth Res Therap. 2009;11(3):R82.
   PubMed Web of Science ®Google Scholar
• Surace MF, Prestamburgo D, Campagnolo M, et al. Presence of NGF and its receptor TrkA in degenerative lumbar facet joint specimens. Eur Spine J. 2009 June;18(Suppl 1):122–125.
   PubMed Web of Science ®Google Scholar
• Janssen announces discontinuation of fulranumab phase 3 development program in osteoarthritis pain Mar 31, 2016 [cited 2019 Dec 1]. Available from: https://www.jnj.com/media-center/press-releases/janssen-announces-discontinuation-of-fulranumab-phase-3-development-program-in-osteoarthritis-pain
   Google Scholar
• Gewandter JS, Dworkin RH, Turk DC, et al. Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations. Pain. 2015 July;156(7):1184–1197.
   PubMed Web of Science ®Google Scholar
• Olsen MF, Bjerre E, Hansen MD, et al. Minimum clinically important differences in chronic pain vary considerably by baseline pain and methodological factors: systematic review of empirical studies. J Clin Epidemiol. 2018 Sept;101:87–106.e2.
   PubMed Web of Science ®Google Scholar
• Deyo RA, Dworkin SF, Amtmann D, et al. Report of the NIH task force on research standards for chronic low back pain. J Pain. 2014 June;15(6):569–585.
   PubMed Web of Science ®Google Scholar
• Katz N, Borenstein DG, Birbara C, et al. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain. 2011 Oct;152(10):2248–2258.
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Gimbel JS, Bramson C, et al. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Pain. 2013 July;154(7):1009–1021.
   PubMed Web of Science ®Google Scholar
• Gimbel JS, Kivitz AJ, Bramson C, et al. Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain. Pain. 2014 Sept;155(9):1793–1801.
   PubMed Web of Science ®Google Scholar
• Pfizer and Lilly announce top-line results from phase 3 study of tanezumab in chronic low back pain Feb 19, 2019 [cited 2019 Dec 1]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_lilly_announce_top_line_results_from_phase_3_study_of_tanezumab_in_chronic_low_back_pain
   Google Scholar
• Tiseo PJ, Ren H, Mellis S. Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study. J Pain Res. 2014;7:523–530.
   PubMed Web of Science ®Google Scholar
• Bannwarth B, Kostine M. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists? Drugs. 2014 Apr;74(6):619–626.
   PubMed Web of Science ®Google Scholar
• Norman BH, McDermott JS. Targeting the nerve growth factor (NGF) pathway in drug discovery. Potential applications to new therapies for chronic pain. J Med Chem. 2017 Jan 12;60(1):66–88.
   PubMed Web of Science ®Google Scholar
• Bannwarth B, Kostine M. Nerve growth factor antagonists: is the future of monoclonal antibodies becoming clearer? Drugs. 2017 Sept;77(13):1377–1387.
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Tive LA, Abramson SB, et al. When is osteonecrosis not osteonecrosis?: Adjudication of reported serious adverse joint events in the Tanezumab clinical development program. Arthritis Rheumatol. 2016 Feb;68(2):382–391.
   PubMed Web of Science ®Google Scholar
• Pfizer and Lilly announce top-line results from long-term phase 3 study of tanezumabin patients with osteoarthritis Apr 18, 2019 [cited 2019 Dec 1]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_lilly_announce_top_line_results_from_long_term_phase_3_study_of_tanezumab_in_patients_with_osteoarthritis
   Google Scholar
• Hochberg MC. Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthritis Cartilage. 2015 Jan;23(Suppl 1):S18–21.
   PubMed Web of Science ®Google Scholar
• Miller RE, Malfait AM, Block JA. Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain. Clin Exp Rheumatol. 2017 Sep–Oct 35 Suppl;107(5):85–87.
   Google Scholar